The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Alzheimer's and Dementia

Volumn 13, Issue 5, 2017, Pages 561-571

  Weiner, Michael W ^a,b,c   Veitch, Dallas P ^a   Aisen, Paul S ^d   Beckett, Laurel A ^e   Cairns, Nigel J ^f   Green, Robert C ^g   Harvey, Danielle ^e   Jack, Clifford R ^h   Jagust, William ⁱ   Morris, John C ^d   Petersen, Ronald C ^h   Salazar, Jennifer ^d   Saykin, Andrew J ^j   Shaw, Leslie M ^k   Toga, Arthur W ^d   Trojanowski, John Q ^l  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ELI LILLY AND COMPANY   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Alzheimer's disease; Amyloid phenotyping; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Functional connectivity; Tau imaging

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLORBETABEN; FLORBETAPIR F 18; PITTSBURGH COMPOUND B; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE MARKER; DRUG UPTAKE; EPISODIC MEMORY; FOLLOW UP; HEREDITY; HUMAN; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; BRAIN; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DISEASE EXACERBATION; SCINTISCANNING;

ALZHEIMER DISEASE; BIOMARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING;

EID: 85008701998     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.10.006     Document Type: Review

References (84)

1. [1] Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12 (2016), 459–509.
2. [2] Satizabal, C.L., Beiser, A.S., Chouraki, V., Chene, G., Dufouil, C., Seshadri, S., Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 374 (2016), 523–532.
3. [3] Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Cedarbaum, J., et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 11 (2015), e1–e120.
4. [4] Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C., Jagust, W., et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 15 (2005), 869–877 xi–xii.
5. [5] Weiner, M.W., Aisen, P.S., Jack, C.R. Jr., Jagust, W.J., Trojanowski, J.Q., Shaw, L., et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6 (2010), 202–211.e7.
6. [6] Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Cedarbaum, J., et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 11 (2015), 865–884.
7. [7] Frisoni, G.B., Weiner, M.W., Alzheimer's Disease Neuroimaging Initiative special issue. Neurobiol Aging 31 (2010), 1259–1262.
8. [8] Thies, W.H., Alzheimer's Disease Neuroimaging Initiative: a decade of progress in Alzheimer's disease. Alzheimers Dement 11 (2015), 727–729.
9. [9] Khachaturian, Z.S., Perspective on the Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6 (2010), 199–201.
10. [10] Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 8 (2012), S1–S68.
11. [11] Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 9 (2013), e111–e194.
12. [12] Landau, S.M., Breault, C., Joshi, A.D., Pontecorvo, M., Mathis, C.A., Jagust, W.J., et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 54 (2013), 70–77.
13. [13] Landau, S.M., Fero, A., Baker, S.L., Koeppe, R., Mintun, M., Chen, K., et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 56 (2015), 567–574.
14. [14] Landau, S.M., Thomas, B.A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41 (2014), 1398–1407.
15. [15] Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
16. [16] Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121 (2011), 597–609.
17. [17] Kang, J.H., Korecka, M., Toledo, J.B., Trojanowski, J.Q., Shaw, L.M., Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers. Clin Chem 59 (2013), 903–916.
18. [18] Salloway, S., Sperling, R., Gregg, K., Yu, P., Joshi, A.D., Lu, M., et al. Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-moderate Alzheimer's disease: results from the phase 3 PET sub-studies of bapineuzumab and solanezumab. Alzheimers Dement 9:4 Suppl (2013), P888–P889.
19. [19] Vellas, B., Carrillo, M.C., Sampaio, C., Brashear, H.R., Siemers, E., Hampel, H., et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 9 (2013), 438–444.
20. [20] Siemers, E.R., Sundell, K.L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 (2016), 110–120.
21. [21] Donohue, M.C., Gamst, A.C., Thomas, R.G., Xu, R., Beckett, L., Petersen, R.C., et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials 32 (2011), 685–693.
22. [22] Donohue, M.C., Gamst, A.C., Aisen, P.S., Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 7 (2011), 245–246 author reply 7–9.
23. [23] Donohue, M.C., Aisen, P.S., Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. J Nutr Health Aging 16 (2012), 360–364.
24. [24] Donohue, M.C., Jacqmin-Gadda, H., Le Goff, M., Thomas, R.G., Raman, R., Gamst, A.C., et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10 (2014), S400–S410.
25. [25] Aisen, P.S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z.S., Dubois, B., et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76 (2011), 280–286.
26. [26] Vellas, B., Hampel, H., Rouge-Bugat, M.E., Grundman, M., Andrieu, S., Abu-Shakra, S., et al. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging 16 (2012), 339–345.
27. [27] Bernick, C., Cummings, J., Raman, R., Sun, X., Aisen, P., Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 69 (2012), 901–905.
28. [28] Grill, J.D., Raman, R., Ernstrom, K., Aisen, P., Karlawish, J., Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology 80 (2013), 282–288.
29. [29] Henley, D.B., Dowsett, S.A., Chen, Y.F., Liu-Seifert, H., Grill, J.D., Doody, R.S., et al. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther, 7, 2015, 43.
30. [30] Grill, J.D., Raman, R., Ernstrom, K., Aisen, P., Dowsett, S.A., Chen, Y.F., et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther, 7, 2015, 39.
31. [31] Sperling, R.A., Jack, C.R. Jr., Aisen, P.S., Testing the right target and right drug at the right stage. Sci Transl Med, 3, 2011, 111cm33.
32. [32] Vellas, B., Aisen, P.S., Sampaio, C., Carrillo, M., Scheltens, P., Scherrer, B., et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 95 (2011), 594–600.
33. [33] Aisen, P.S., Vellas, B., Hampel, H., Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov, 12, 2013, 324.
34. [34] Andrieu, S., Coley, N., Lovestone, S., Aisen, P.S., Vellas, B., Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14 (2015), 926–944.
35. [35] Salmon, D.P., Ferris, S.H., Thomas, R.G., Sano, M., Cummings, J.L., Sperling, R.A., et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology 27 (2013), 391–401.
36. [36] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
37. [37] Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
38. [38] Sano, M., Raman, R., Emond, J., Thomas, R.G., Petersen, R., Schneider, L.S., et al. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord 25 (2011), 122–127.
39. [39] Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
40. [40] Liu-Seifert, H., Siemers, E., Sundell, K., Price, K., Han, B., Selzler, K., et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis 43 (2015), 949–955.
41. [41] Amariglio, R.E., Donohue, M.C., Marshall, G.A., Rentz, D.M., Salmon, D.P., Ferris, S.H., et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol 72 (2015), 446–454.
42. [42] Hedden, T., Oh, H., Younger, A.P., Patel, T.A., Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80 (2013), 1341–1348.
43. [43] Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71 (2012), 362–381.
44. [44] Fox, N.C., Black, R.S., Gilman, S., Rossor, M.N., Griffith, S.G., Jenkins, L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005), 1563–1572.
45. [45] Salloway, S., Sperling, R., Keren, R., Porsteinsson, A.P., van Dyck, C.H., Tariot, P.N., et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77 (2011), 1253–1262.
46. [46] Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73 (2009), 2061–2070.
47. [47] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
48. [48] Novak, G., Einstein, S., Tudor, I.C., Gregg, K., Collins, P., Wyman, B., et al. The rate of clinical progression and brain atrophy is greater with increasing severity of Alzheimer's disease: results from the volumetric MRI substudies of two phase III trials with bapineuzumab. Alzheimers Dement, 9, 2013, 287.
49. [49] Saumier, D., Aisen, P.S., Gauthier, S., Vellas, B., Ferris, S.H., Duong, A., et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J Nutr Health Aging 13 (2009), 370–372.
50. [50] Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 (1995), 271–278 discussion 8–84.
51. [51] Ossenkoppele, R., Schonhaut, D.R., Baker, S.L., O'Neil, J.P., Janabi, M., Ghosh, P.M., et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 77 (2015), 338–342.
52. [52] Villemagne, V.L., Fodero-Tavoletti, M.T., Masters, C.L., Rowe, C.C., Tau imaging: early progress and future directions. Lancet Neurol 14 (2015), 114–124.
53. [53] Portelius, E., Zetterberg, H., Skillback, T., Tornqvist, U., Andreasson, U., Trojanowski, J.Q., et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 138:Pt 11 (2015), 3373–3385.
54. [54] Sperling, R.A., Jack, C.R. Jr., Black, S.E., Frosch, M.P., Greenberg, S.M., Hyman, B.T., et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7 (2011), 367–385.
55. [55] Kang, J.H., Korecka, M., Figurski, M.J., Toledo, J.B., Blennow, K., Zetterberg, H., et al. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimers Dement 11 (2015), 772–791.
56. [56] Kaddurah-Daouk, R., Zhu, H., Sharma, S., Bogdanov, M., Rozen, S.G., Matson, W., et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry, 9, 2013, 18.
57. [57] Motsinger-Reif, A.A., Zhu, H., Kling, M.A., Matson, W., Sharma, S., Fiehn, O., et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun, 1, 2013, 28.
58. [58] Weiner, M.W., Veitch, D.P., Hayes, J., Neylan, T., Grafman, J., Aisen, P.S., et al. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 10 (2014), S226–S235.
59. [59] Ivanova, I., Salmon, D.P., Gollan, T.H., The multilingual naming test in Alzheimer's disease: clues to the origin of naming impairments. J Int Neuropsychol Soc 19 (2013), 272–283.
60. [60] Gerstenecker, A., Eakin, A., Triebel, K., Martin, R., Swenson-Dravis, D., Petersen, R.C., et al. Age and education corrected older adult normative data for a short form version of the Financial Capacity Instrument. Psychol Assess 28 (2016), 737–749.
61. [61] Maruff, P., Lim, Y.Y., Darby, D., Ellis, K.A., Pietrzak, R.H., Snyder, P.J., et al. Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychol, 1, 2013, 30.
62. [62] Darby, D.G., Pietrzak, R.H., Fredrickson, J., Woodward, M., Moore, L., Fredrickson, A., et al. Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimers Dement 8 (2012), 95–104.
63. [63] Sabri, O., Sabbagh, M.N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement 11 (2015), 964–974.
64. [64] Scholl, M., Lockhart, S.N., Schonhaut, D.R., O'Neil, J.P., Janabi, M., Ossenkoppele, R., et al. PET imaging of tau deposition in the aging human brain. Neuron 89 (2016), 971–982.
65. [65] Alsop, D.C., Detre, J.A., Golay, X., Gunther, M., Hendrikse, J., Hernandez-Garcia, L., et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 73 (2015), 102–116.
66. [66] de Flores, R., La Joie, R., Landeau, B., Perrotin, A., Mezenge, F., de La Sayette, V., et al. Effects of age and Alzheimer's disease on hippocampal subfields: comparison between manual and FreeSurfer volumetry. Hum Brain Mapp 36 (2015), 463–474.
67. [67] Mueller, S., Yushkevich, P., Wang, L., Van Leemput, K., Mezher, A., Iglesias, J.E., et al. Collaboration for a systematic comparison of different techniques to measure subfield volumes: announcement and first results. Alzheimers Dement, 9, 2013, P51.
68. [68] Pluta, J., Yushkevich, P., Das, S., Wolk, D., In vivo analysis of hippocampal subfield atrophy in mild cognitive impairment via semi-automatic segmentation of T2-weighted MRI. J Alzheimers Dis 31 (2012), 85–99.
69. [69] Yushkevich, P.A., Pluta, J.B., Wang, H., Xie, L., Ding, S.L., Gertje, E.C., et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp 36 (2015), 258–287.
70. [70] Korecka, M., Waligorska, T., Figurski, M., Toledo, J.B., Arnold, S.E., Grossman, M., et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 41 (2014), 441–451.
71. [71] Leinenbach, A., Pannee, J., Dulffer, T., Huber, A., Bittner, T., Andreasson, U., et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 60 (2014), 987–994.
72. [72] Pannee, J., Gobom, J., Shaw, L.M., Korecka, M., Chambers, E.E., Lame, M., et al. Round robin test on quantification of amyloid-beta 1-42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement 12 (2016), 55–59.
73. [73] Bittner, T., Zetterberg, H., Teunissen, C., Ostlund, R.E., Militello, M., Andreasson, U., et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid(1-42) in human cerebrospinal fluid. Alzheimers Dement 12 (2015), 517–526.
74. [74] Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
75. [75] Saykin, A.J., Shen, L., Yao, X., Kim, S., Nho, K., Risacher, S.L., et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement 11 (2015), 792–814.
76. [76] Shen, L., Thompson, P.M., Potkin, S.G., Bertram, L., Farrer, L.A., Foroud, T.M., et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav 8 (2014), 183–207.
77. [77] Mukherjee, S., Kim, S., Ramanan, V.K., Gibbons, L.E., Nho, K., Glymour, M.M., et al. Gene-based GWAS and biological pathway analysis of the resilience of executive functioning. Brain Imaging Behav 8 (2014), 110–118.
78. [78] Ramanan, V.K., Risacher, S.L., Nho, K., Kim, S., Shen, L., McDonald, B.C., et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain 138 (2015), 3076–3088.
79. [79] Jahanshad, N., Rajagopalan, P., Hua, X., Hibar, D.P., Nir, T.M., Toga, A.W., et al. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A 110 (2013), 4768–4773.
80. [80] Jack, C.R. Jr., Knopman, D.S., Chetelat, G., Dickson, D., Fagan, A.M., Frisoni, G.B., et al. Suspected non-Alzheimer disease pathophysiology—concept and controversy. Nat Rev Neurol 12 (2016), 117–124.
81. [81] Jack, C.R. Jr., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.
82. [82] Bramblett, G.T., Trojanowski, J.Q., Lee, V.M., Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab Invest 66 (1992), 212–222.
83. [83] Montine, T.J., Montine, K.S., Precision medicine: clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. J Exp Med 212 (2015), 601–605.
84. [84] Perry, D., Sperling, R., Katz, R., Berry, D., Dilts, D., Hanna, D., et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother 15 (2015), 327–333.